July 14, 2020

Michael Raab President and Chief Executive Officer Ardelyx, Inc. 34175 Ardenwood Blvd. Fremont, CA 94555

> Re: Ardelyx, Inc. Registration

Statement on Form S-3

Filed July 9, 2020 File No. 333-239764

Dear Mr. Raab:

We have limited our review of your registration statement to those issues we have

addressed in our comment.

Please respond to this letter by amending your registration statement and providing the

requested information. If you do not believe our comment applies to your facts and

circumstances or do not believe an amendment is appropriate, please tell us why in your

response.

After reviewing any amendment to your registration statement and the information vou

provide in response to this comment, we may have additional comments.

Registration Statement on Form S-3 filed July 9, 2020

General

1.

We note that your forum selection provision identifies the Court of Chancery of the State of Delaware as the exclusive forum for certain litigation, including any "derivative action." Please disclose whether this provision applies to actions arising under the Securities Act or Exchange Act. In that regard, we note that Section 27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder, and Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder. If the provision applies to Securities Act claims, please also revise your prospectus to state that there is uncertainty as to whether a court would enforce such provision and that investors cannot waive compliance with the federal securities laws and Michael Raab Ardelyx, Inc. July 14, 2020 Page 2 the rules and regulations thereunder. If this provision does not apply to

actions arising

under the Securities Act or Exchange Act, please also tell us how you will inform

investors in future filings that the provision does not apply to any actions arising under the

Securities Act or Exchange Act.

We remind you that the company and its management are responsible for the accuracy

and adequacy of their disclosures, notwithstanding any review, comments, action or absence of

action by the staff.

Refer to Rules 460 and 461 regarding requests for acceleration. Please allow adequate time for us to review any amendment prior to the requested effective date of the registration statement.

You may contact Jeffrey Gabor at 202-551-2544 or Mary Beth Breslin at 202-551-3625 with any questions.

Sincerely,

FirstName LastNameMichael Raab

Division of

Corporation Finance Comapany NameArdelyx, Inc.

Office of Life

Sciences
July 14, 2020 Page 2
cc: Mark V. Roeder, Esq.
FirstName LastName